The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 23, 2016
Filed:
May. 10, 2013
Applicant:
Reset Therapeutics, Inc., Burlingame, CA (US);
Inventors:
Ross Bersot, Orinda, CA (US);
Paul Humphries, Santa Clara, CA (US);
Assignee:
RESET THERAPEUTICS, INC., South San Francisco, CA (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 493/08 (2006.01); C07D 209/86 (2006.01); C07D 209/88 (2006.01); A61K 31/403 (2006.01); A61K 31/541 (2006.01); A61K 31/549 (2006.01); A61P 3/00 (2006.01); A61K 31/4155 (2006.01); A61K 31/427 (2006.01); A61K 45/06 (2006.01); C07D 417/06 (2006.01); C07D 401/06 (2006.01); C07D 403/06 (2006.01); C07D 409/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/549 (2013.01); A61K 31/403 (2013.01); A61K 31/4155 (2013.01); A61K 31/427 (2013.01); A61K 31/541 (2013.01); A61K 45/06 (2013.01); C07D 209/86 (2013.01); C07D 209/88 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01); C07D 417/06 (2013.01); C07D 493/08 (2013.01);
Abstract
The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R, R, R, R, R, R, R, A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.